Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: Study protocol of a retrospective cohort study using the QResearch general practice database

BMJ Open

Volumn 4, Issue 8, 2014, Pages

  Kotz, Daniel ^a,b,c   Simpson, Colin ^c   Viechtbauer, Wolfgang ^d   Van Schayck, Onno C P ^a,c   West, Robert ^b   Sheikh, Aziz ^a,c,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; VARENICLINE; ANTIDEPRESSANT AGENT; BENZAZEPINE DERIVATIVE; NICOTINE GUM; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; COHORT ANALYSIS; DATA BASE; DRUG SAFETY; FOLLOW UP; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; NEUROPSYCHIATRY; NICOTINE REPLACEMENT THERAPY; PEER REVIEW; PRESCRIPTION; RETROSPECTIVE STUDY; SMOKING CESSATION; VERY ELDERLY; COMPARATIVE STUDY; DRUG THERAPY; EPIDEMIOLOGY; PREVENTION AND CONTROL; PROCEDURES; SMOKING; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZAZEPINES; BUPROPION; COHORT STUDIES; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; NICOTINIC AGONISTS; QUINOXALINES; RETROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84938750947     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005281     Document Type: Article

References (57)

1. World Health Organisation (WHO). WHO report on the global tobacco epidemic. Warning about the dangers of tobacco . Geneva, 2011.
2. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368:341-50.
3. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013;368:351-64.
4. World Health Organisation (WHO). Global burden of disease. http://www.who.int/mediacentre/factsheets/fs310/en/index.html (accessed 24 Apr 2012).
5. Secondary Global burden of disease. http://www.who.int/mediacentre/ factsheets/fs310/en/index.html (accessed 24 Apr 2012).
6. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society Public Policy Statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693-718.
7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic pulmonary disease. Revised 2011. http://www.goldcopd.com (accessed 24 Apr 2012).
8. Secondary Global strategy for the diagnosis, management, and prevention of chronic pulmonary disease. Revised 2011. http://www.goldcopd.com (accessed 24 Apr 2012).
9. Pride NB. Smoking cessation: effects on symptoms, spirometry and future trends in COPD. Thorax 2001;56(Suppl 2):ii7-10.
10. Tønnesen P, Carrozzi L, Fagerstrom KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. ERS task force guideline. Eur Respir J 2007;29:390-417. (Pubitemid 46231920)
11. Shahab L, Jarvis MJ, Britton J, et al. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006;61:1043-7. (Pubitemid 44852021)
12. Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology of chronic obstructive pulmonary disease in England: a national study of 51 804 patients. Br J Gen Pract 2010;60:e277-84.
13. National Institute for Health and Clinical Excellence (NICE). Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities . London, 2008.
14. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 123. Varenicline for smoking cessation. London, 2007.
15. Cahill K, Stead Lindsay F, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; (4):CD006103.
16. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63:717-24.
17. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD. Chest 2011;139:591-9.
18. Warnier MJ, Riet EE, Rutten FH, et al. Smoking cessation strategies in patients with chronic obstructive pulmonary disease. Eur Respir J 2013;41:727-34.
19. Kotz D, Fidler JA, West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res 2011;13:793-9.
20. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-66.
21. Harrison-Woolrych M, Maggo S, Tan M, et al. Cardiovascular Events in Patients taking Varenicline. Drug Saf 2012;35:33-43.
22. Farrell M, Howes S, Bebbington P, et al. Nicotine, alcohol and drug dependence and psychiatric comorbidity: Results of a national household survey. Br J Psychiatry 2001;179:432-7. (Pubitemid 33097166)
23. Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend 2008;98:169-78.
24. European Medicines Agency. European Medicines Agency concludes new advice to doctors and patients for Champix needed. EMEA press office, 14 December 2007.
25. US Food and Drug Administration. Varenicline (marketed as Chantix) Information. FDA ALERT [2/1/2008]. US Food and Drug Administration, 2 January 2008.
26. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805.
27. Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012;345:e7176.
28. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012;344:e2856.
29. Pasternak B, Svanström H, Hviid A. Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction 2013;108:1336-43.
30. Thomas KH, Martin RM, Davies NM, et al. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ 2013;347:f5704.
31. Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012;345:e7176.
32. Buggy Y, Cornelius V, Fogg C, et al. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Drug Saf 2013;36:521-31.
33. Meyer TE, Taylor LG, Xie S, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction 2013;108:203-10.
34. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099-107. (Pubitemid 41507547)
35. Sutton AJ, Cooper NJ, Lambert PC, et al. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res 2002;2:367-79.
36. Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop-smoking medications. Nicotine Tob Res 2012;14:1483-7.
37. Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy. Tob Control 2005;14:346-55. (Pubitemid 41396483)
38. West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study. Thorax 2007;62:998-1002. (Pubitemid 350084500)
39. Hippisley-Cox J, Fielding K, Pringle M. Depression as a risk factor for ischaemic heart disease in men: population based case-control study. BMJ 1998;316:1714-19. (Pubitemid 28254425)
40. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
41. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 2005;330:1059-63. (Pubitemid 40646559)
42. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366.
43. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013;346:f2573.
44. Reeves D, Springate DA, Ashcroft DM, et al. Can analyses of electronic patient records be independently and externally validated? The effect of statins on the mortality of patients with ischaemic heart disease: a cohort study with nested case-control analysis. BMJ Open 2014;4:e004952.
45. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 2013;346:f114.
46. Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 2010:c2442.
47. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6. (Pubitemid 29296676)
48. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the North. London: Croom Helm, 1988.
49. Khan N, Perera R, Harper S, et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1.
50. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat med 1982;1:121-9. (Pubitemid 13146129)
51. Stürmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59:437-47.
52. Sturmer T, Rothman KJ, Avorn J, et al. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution - a simulation study. Am J Epidemiol 2010;172:843-54.
53. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009;51:171-84.
54. Ho D, Imai K, King G, et al. MatchIt: Nonparametric preprocessing for parametric causal inference. J Stat Software 2011;42:1-28.
55. Rassen JA, Brookhart MA, Glynn RJ, et al . Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol 2009;62:1226-32.
56. Chen Y, Briesacher BA. Use of instrumental variable in prescription drug research with observational data: a systematic review. J Clin Epidemiol 2011;64:687-700.
57. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9. (Pubitemid 351289042)